Cyxone’s Investigational T20K Therapy Shows Potential for Treating IBD in Preclinical Study

Cyxone’s Investigational T20K Therapy Shows Potential for Treating IBD in Preclinical Study
A preclinical study found that Cyxone’s investigational T20K therapy was able to reduce the immune system’s activity in an animal model of inflammatory bowel disease (IBD), showing promise as a treatment for the disease.  T20K belongs to a family of natural peptides derived from plants called cyclotides. Researchers found that cyclotides are able to inhibit the cytokine interleukin-2

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *